financetom
Business
financetom
/
Business
/
Bajaj Finserv's Sanjiv Bajaj takes over as CII president
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bajaj Finserv's Sanjiv Bajaj takes over as CII president
May 12, 2022 10:06 AM

Sanjiv Bajaj, chairman and managing director of Bajaj Finserv Limited, has assumed office as the president of CII for 2022-23, the industry body said on Thursday. He takes over from T V Narendran, CEO and managing director of Tata Steel Limited.

Share Market Live

NSE

Hero MotoCorp Ltd Chairman and CEO Pawan Munjal is the CII President-Designate for 2022-23, whereas TVS Supply Chain Solutions Executive Vice Chairman R Dinesh takes over as CII Vice President.

"Sanjiv has been engaged with CII for many years at the State, Regional and National level. He was the President-Designate for 2021-22 and the Chairman of the Western Region during 2019-20," CII stated.

Also read:

CII president says corporate India must think outside incentives and subsidies

Bajaj is an alumnus of the Harvard Business School, US. He is a member of the board of Indian School of Business (ISB); Member of the International Advisory Board, Allianz SE and the International Technology Advisory Panel of Monetary Authority of Singapore and Regional Stewardship Board for India and South Asia 2019-2020 of the World Economic Forum, the industry body shared.

President-Designate Munjal has been closely associated with CII for almost 30 years. He has been the chairman of CII Northern Region during 1996-97 and has led several CII National Committees, including on sports, environment, and technology and innovation.

Dinesh is a commerce graduate and an associate member of the Institute of Chartered Accountants of India and Institute of Cost and Works Accountants of India.

Also read: Toppling trade barriers high on agenda as CII signs pact with UK's biggest business body CBI

(Edited by : Anand Singha)

First Published:May 12, 2022 7:06 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brookfield-led consortium to invest in GEMS Education
Brookfield-led consortium to invest in GEMS Education
Jun 18, 2024
June 18 (Reuters) - A consortium led by Brookfield Asset Management ( BAM ) has agreed to invest in Dubai-based international education provider GEMS Education, the companies said in a joint statement on Tuesday. They did not specify the size of the investment, but said private equity firm CVC Capital partners will substantially exit its stake in GEMS as part...
KBR Lands $46 Million Contract to Advise Iraqi Government on Infrastructure, 'Mega'-Projects
KBR Lands $46 Million Contract to Advise Iraqi Government on Infrastructure, 'Mega'-Projects
Jun 18, 2024
09:27 AM EDT, 06/18/2024 (MT Newswires) -- KBR (KBR) early Tuesday said it has received a new five-year contract valued at around $46 million from the Iraqi government to assist with infrastructure and future energy projects. Under the terms of the Ministry of Planning contract, the company will provide advisory and consulting services to the Iraqi government, with a particular...
BRIEF-Workiva Entered Into Agreement And Plan Of Merger With Sustain.Life
BRIEF-Workiva Entered Into Agreement And Plan Of Merger With Sustain.Life
Jun 18, 2024
June 18 (Reuters) - Workiva Inc ( WK ): * WORKIVA INC ( WK ): ON JUNE 17, CO ENTERED AGREEMENT AND PLAN OF MERGER WITH SUSTAIN.LIFE, INC * WORKIVA INC ( WK ): MERGER CLOSED SIMULTANEOUSLY WITH EXECUTION OF MERGER AGREEMENT FOR TOTAL PURCHASE PRICE OF $100 MILLION Source text for Eikon: Further company coverage: ...
Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe
Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe
Jun 18, 2024
09:28 AM EDT, 06/18/2024 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Tuesday that they have signed a partnership agreement to supply and commercialize Alvotech's ( ALVO ) proposed biosimilar to Eylea in Europe. Financial terms of the partnership weren't disclosed. Alvotech ( ALVO ) is currently developing AVT06, a proposed low-dose biosimilar to Eylea, and AVT29,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved